A study of her-2/ neu oncogene expression in benign and malignant ovarian tumors

  • Dr. Sumit Gupta Associate Professor, Department of Pathology, N.I.M.S Medical College, Jaipur, Rajasthan, India
  • Dr Manju Mehra Professor, Department of Pathology, N.I.M.S Medical College, Jaipur, Rajasthan, India
  • Dr Jyotsana Khattri Assistant Professor, Department of Pathology, N.I.M.S Medical College, Jaipur, Rajasthan, India
  • Dr Madhvi Junior Resident, Department of Pathology, N.I.M.S Medical College, Jaipur, Rajasthan, India
DOI: https://doi.org/10.17511/ijmrr.2020.i02.06
Keywords: Her-2/neuprotoncogene, Ovarian cancer, Epithelial tumors

Abstract

Background: Ovarian cancers are very common worldwide with serous epithelial tumors being the most common. Her-2/neuprotoncogene encodes a protein belonging to the EGFR tyrosine kinase receptor family. Overexpression has been shown for poor prognosis in breast cancer. The study was done to find the association of ovarian tumors with Her-2/neu expression.

Aim and objectives: To assess the clinicopathological profile of various ovarian tumors with special reference to age, histological type, grade, and stage of the tumor. To assess and compare the expression of Her-2/neu oncogene in benign and malignant ovarian tumors in relation to age, histological type, grade, and stage of the tumor.

Method: The prospective study was done on 37 specimens received in the Department of Pathology; NIMS medical college from the period between 2015 to 2019.

Results: All the benign and borderline tumors were negative for her-2/neu .48.6% of malignant tumors were her-2/neu positive.

Conclusion: Her-2/neu positivity was seen in 24.3% of ovarian tumors. All the benign and borderline tumors were negative for her-2/neu. 48.6% of malignant tumors were her-2/neu positive.

Downloads

Download data is not yet available.

References

Deodhar KK, Suryawanshi P, Shah M, Rekhi B, Chinoy RF. Immature teratoma of the ovary: a clinicopathological study of 28 cases. Indian J Pathol Microbiol. 2011;54(4):730-735. Available from: http://www.ijpmonline.org/text.asp?2011/54/4/730/91508.

Swamy GG, Satyanarayana N. Clinicopathological analysis of ovarian tumors-A study on five years samples. Nepal Med Coll J. 2010;12(4):221-223.

Whiiermore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk studies collaborative analysis of 12 us case-control studies: II: invasive epithelial ovarian cancers in white women collaborative ovarian cancer group. Am J Epidemiol.1992;136(10):1184-1203. doi: https://doi.org/10.1093/oxfordjournals.aje.a116427.

Yarden Y, Slinkwoshi M. Untangling the Erb B signalling network. Nat Rev Mol Cell Biol.2001;2(2):127-137. doi: https://doi.org/10.1038/35052073.

Smith RA, Cokkinides V, von Eschenbach AC, Levin B, Cohen C, Runowicz CD, et al. American Cancer Society guidelines for the early detection of cancer. CA Cancer J Clinic. 2002;52(1):8-22. doi: https://doi.org/10.3322/canjclin.52.1.8.

Tyagi SP, Madn A. Epithelial tumors of the ovary. Indian J Pathol Microbiol. 1978;21:281-289.

Hellstrom I, Goodman G, Pullman J, Yang Y, Hellstorm KE. Overexpression of Her 2 neu in ovarian cacinomas. Cancer Res.2001;61(6):2420-2423.

Kacinski BM, Mayer AG, King BL, Carter D. NEU protein overexpression in benign, borderline and malignant ovarian neoplasms. Gyneco. Oncol. 1992;44(3):245-253. doi: https://doi.org/10.1016/0090-8258(92)90051-J.

Marwah N, Bansal C, Gupta S, Singh S, Arora B. Immunohistochemical study of the expression of HER-2/neu oncogene in ovarian lesions. Indian J Pathol Microbiol. 2007;50(3):489-492.

Nielsen SN, Scheithauer BW, Gaffey TA. Gliomatosis peritonei. Cancer. 1985;56(10):2499-2503. https://doi.org/10.1002/1097-0142(19851115)56:10%3C2499::aid-cncr2820561029%3E3.0.co;2-0.

Sueblinvong T, Manchana T, Khemapech N, Triratanachat S, Termrungruanglert W, Tresukosol D. Lack of prognostic significance of HER-2/neu in early epithelial ovarian cancer. Asian Pac J Cancer Prev. 2007;8(4):502-506.

Marinaş MC, Mogoş G, Ciurea R, Mogoş DG. EGFR, HER2/neu and Ki67 immunoexpression in serous ovarian tumors. Rom J Morphol Embryol. 2012;53(3):563-567.

Rubin SC, Finstad CL, Wong GY ,Almadrones L, Llyod KO. Pognostic significance of HER -2/neu expression in advanced epithelial ovarian cancer;a multivariate analysis. Am J Obstet Gynecol. 1993;168:162-169.

Singleton TP, Perrone T, Oakley G, Carson L, Niehans GA, Cha SS, et al. Activation of c-erbB-2 and prognosis in ovarian carcinomas. Cancer 1994;73(5):1460-1466. doi: https://doi.org/10.1002/1097-0142(19940301)73:5%3C1460::aid-cncr2820730523%3E3.0.co;2-z.

Høgdall EV, Christensen L, Kjaer SK, Blaakaer J, Bock JE, Glud E, et al. Distribution of HER‐2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: From the Danish “MALOVA” Ovarian Cancer Study. Cancer. 2003;98(1):66-73. https://doi.org/10.1002/cncr.11476.

Luo H, Xu X, Ye M, Sheng B, Zhu X. The prognostic value of HER2 in ovarian cancer: a meta-analysis of observational studies. PloS one. 2018;13(1). doi: https://doi.org/10.1371/journal.pone.0191972.

CITATION
DOI: 10.17511/ijmrr.2020.i02.06
Published: 2020-04-30
How to Cite
1.
Gupta S, Mehra M, Khattri J, Madhvi M. A study of her-2/ neu oncogene expression in benign and malignant ovarian tumors. Int J Med Res Rev [Internet]. 2020Apr.30 [cited 2024Nov.13];8(2):169-75. Available from: https://ijmrr.medresearch.in/index.php/ijmrr/article/view/1181
Issue
Vol 8 No 2 (2020): Mar-Apr
Section
Original Article

Copyright (c) 2020 Author (s). Published by Siddharth Health Research and Social Welfare Society

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.